An end-of-study subgroup analysis of black patients from the phase 2 griffin study of daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM) Meeting Abstract
| Authors: | Nooka, A. K.; Kaufman, J. L.; Rodriguez, C.; Jakubowiak, A.; Efebera, Y. A.; Reeves, B.; Wildes, T. M.; Holstein, S. A.; Anderson, L. D. Jr; Badros, A. Z.; Shune, L. O.; Chari, A.; Pei, H.; Cortoos, A.; Patel, S.; Lin, T. S.; Richardson, P. G.; Usmani, S.; Voorhees, P. M. |
| Abstract Title: | An end-of-study subgroup analysis of black patients from the phase 2 griffin study of daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM) |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 10154 |
| End Page: | 10156 |
| Language: | English |
| ACCESSION: | WOS:000893230303072 |
| DOI: | 10.1182/blood-2022-162473 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
